Recent Updates
Recently added Catalysts

BB2603-1

Phase 2

Distal Subungual Onychomycosis | Small molecule | Infectious Disease |IQVIA Holdings, Inc.|Last Updated: Aug 1, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment111
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04188574A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the ToenailPHASE2 COMPLETED 111Mar 22, 2021Jun 28, 2023Aug 1, 202320 Czechia, Germany +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of subjects with an Early Response for BB2603-10 versus vehicle
16 weeks

Early Response is defined as clinimetrically assessed clear nail growth (yes/no) and/or negative dermatophyte culture (yes/no).

Secondary Endpoints
Number of subjects with a Complete Cure for BB2603-10 versus vehicle
52 weeks
Number of subjects with Completely Clear Nail, Almost Clear Nail, Negative KOH or Negative Dermatocyte Culture, assessed separately, for BB2603-10 versus vehicle
52 weeks
Concentration of terbinafine in the plasma in all subjects
52 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
BB2603-10EXPERIMENTALTreatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
BB2603-3EXPERIMENTALTreatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
BB2603-1EXPERIMENTALTreatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine
Vehicle ControlOTHER0.3% polyhexanide/ 20% ethanol/ water formulation.
Interventions
NameTypeDescription
BB2603-1DRUGTreatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
BB2603-3DRUGTreatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
BB2603-10DRUGTreatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
VehicleOTHERTreatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 99 Years
SexALL
Healthy VolunteersNo
Study Sites20

Inclusion Criteria: 1. Male or female ≥18 (and ≤99) at the time of Informed Consent. 2. Clinically and mycologically (KOH and culture positive for dermatophytes \[microbial infection with fungus belonging to the genus Trichophyton, Microsporum, Epidermophyton\]) confirmed diagnoses of DSO of the ta...

Countries:CzechiaGermanyPoland
Unlock Eligibility Criteria